Marinus Pharmaceuticals Balance Sheet

Financials in millions PKR. Fiscal year is October - September.

Millions PKR. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020
Cash & Equivalents	194.93	88.48	46.87	33.34	10.93	10.27
Short-Term Investments	1,694	-	-	20.06	50.68	144.17
Trading Asset Securities	-	627.22	913.98	712.36	1,266	963.91
Cash & Short-Term Investments	1,889	715.7	960.85	765.77	1,328	1,118
Cash Growth	46.56%	-25.51%	25.48%	-42.34%	18.75%	-32.98%
Accounts Receivable	155.65	479.4	288.6	100.42	69.67	18.21
Other Receivables	-	0.84	119.03	58.52	56.21	40.18
Receivables	423.91	614.56	536.9	162.32	128.55	61.68
Inventory	2,661	2,795	757.05	1,722	695.83	187.75
Prepaid Expenses	-	-	-	-	4.08	4
Other Current Assets	10.24	62.8	77.96	71.23	54.7	43.34
Total Current Assets	4,984	4,189	2,333	2,721	2,211	1,415
Property, Plant & Equipment	2,347	2,486	2,464	2,498	2,424	2,305
Long-Term Investments	1,246	1,126	1,804	1,167	1,052	1,193
Other Long-Term Assets	3.44	3.44	3.44	209.96	205.51	278.43
Total Assets	8,581	7,804	6,604	6,596	5,893	5,192
Accounts Payable	1,075	140.3	105.21	125.52	155.21	157.08
Accrued Expenses	361.98	845.06	704.95	608.77	418.41	439.95
Short-Term Debt	2,075	2,680	14.21	1,258	1,064	297.98
Current Portion of Long-Term Debt	141.36	112.3	100.64	386.35	372.26	112.81
Current Portion of Leases	-	51.04	15.14	12.9	16.22	13.01
Current Income Taxes Payable	6.78	-	-	-	-	-
Current Unearned Revenue	-	73.59	433	512.48	38.05	38.9
Other Current Liabilities	30.85	76.45	83.63	63.14	54.77	51.59
Total Current Liabilities	3,690	3,979	1,457	2,967	2,119	1,111
Long-Term Debt	228.92	289.78	391.5	642.02	922.59	1,126
Long-Term Leases	36.71	76.47	48.6	33.55	30.6	29.26
Long-Term Unearned Revenue	60.4	75.7	98.72	103.37	70.76	3.61
Long-Term Deferred Tax Liabilities	556.76	542.69	678.77	47.09	79.58	170.97
Other Long-Term Liabilities	49.93	57	46.84	49.45	170.47	147.97
Total Liabilities	4,625	5,024	2,725	3,847	3,397	2,593
Common Stock	749.28	749.28	749.28	605.48	489.27	465.97
Additional Paid-In Capital	63.28	63.28	63.28	63.28	63.28	63.28
Retained Earnings	3,139	1,964	3,062	2,077	1,949	2,056
Comprehensive Income & Other	4.06	4.06	4.04	3.81	-5.73	13
Shareholders' Equity	3,955	2,780	3,879	2,749	2,496	2,599
Total Liabilities & Equity	8,581	7,804	6,604	6,596	5,893	5,192
Total Debt	2,482	3,210	570.1	2,333	2,406	1,579
Net Cash (Debt)	-592.74	-2,494	390.75	-1,567	-1,078	-460.53
Net Cash Per Share	-7.91	-33.29	5.22	-20.92	-14.53	-6.15
Filing Date Shares Outstanding	74.92	74.93	74.93	74.93	74.93	74.93
Total Common Shares Outstanding	74.92	74.93	74.93	74.93	74.93	74.93
Working Capital	1,293	209.63	875.97	-245.73	92.35	303.78
Book Value Per Share	52.79	37.11	51.77	36.69	33.31	34.68
Tangible Book Value	3,955	2,780	3,879	2,749	2,496	2,599
Tangible Book Value Per Share	52.79	37.11	51.77	36.69	33.31	34.68
Land	-	83.39	83.39	83.39	83.39	83.39
Buildings	-	464.4	463.58	457.35	453.74	453.74
Machinery	-	4,038	3,878	3,720	3,314	3,229
Construction In Progress	-	152.12	188.58	233.99	403.49	126.36

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q